Bausch Health Financials
| BHC Stock | USD 7.44 0.21 2.75% |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.99 | 1.5 |
|
|
Investors should never underestimate Bausch Health's ability to pay suppliers on time, ensure interest payments are not accumulating, and correctly time where and how to reinvest extra cash. Individual investors need to monitor Bausch Health's cash flow, debt, and profitability to make informed and accurate decisions about investing in Bausch Health Companies.
Cash And Equivalents |
|
Bausch | Select Account or Indicator |
Understanding current and past Bausch Health Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Bausch Health's financial statements are interrelated, with each one affecting the others. For example, an increase in Bausch Health's assets may result in an increase in income on the income statement.
Bausch Health Companies Earnings Geography
Please note, the presentation of Bausch Health's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Bausch Health's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Bausch Health's management manipulating its earnings.
Bausch Health Stock Summary
Bausch Health competes with Viatris, Tilray, Zoetis, Emergent Biosolutions, and Neurocrine Biosciences. Bausch Health Companies Inc., together with its subsidiaries, develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. Bausch Health Companies Inc. is headquartered in Laval, Canada. Bausch Health is traded on New York Stock Exchange in the United States.| Foreign Associate | Canada |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Instrument | USA Stock View All |
| Exchange | New York Stock Exchange |
| ISIN | CA0717341071 |
| CUSIP | 91911K102 071734107 09067J109 09067K106 |
| Location | Quebec; Canada |
| Business Address | 2150 St ElzEar |
| Sector | Pharmaceuticals |
| Industry | Health Care |
| Benchmark | Dow Jones Industrial |
| Website | www.bauschhealth.com |
| Phone | 514 744 6792 |
| Currency | USD - US Dollar |
Bausch Health Key Financial Ratios
| Return On Equity | -23.05 | ||||
| Profit Margin | (0.02) % | ||||
| Operating Margin | 0.22 % | ||||
| Price To Sales | 0.30 X | ||||
| Revenue | 8.76 B |
Bausch Health Key Balance Sheet Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Total Assets | 31.2B | 29.2B | 25.7B | 27.4B | 31.5B | 33.0B | |
| Other Current Liab | 4.6B | 4.8B | 2.9B | 3.1B | 3.5B | 3.7B | |
| Net Debt | 23.3B | 22.1B | 20.2B | 21.4B | 24.7B | 25.9B | |
| Retained Earnings | (8.0B) | (9.0B) | (9.2B) | (9.8B) | (8.8B) | (8.4B) | |
| Accounts Payable | 337M | 407M | 521M | 719M | 826.9M | 868.2M | |
| Cash | 605M | 582M | 564M | 947M | 1.1B | 1.1B | |
| Net Receivables | 1.6B | 1.8B | 1.8B | 2.0B | 2.3B | 2.4B | |
| Other Current Assets | 855M | 720M | 803M | 1.1B | 1.3B | 1.3B | |
| Total Liab | 30.6B | 29.2B | 25.4B | 27.4B | 31.5B | 33.1B | |
| Total Current Assets | 5.3B | 5.6B | 4.2B | 5.6B | 6.4B | 6.8B | |
| Short Term Debt | 52M | 49.9M | 482M | 450M | 517.5M | 543.4M | |
| Intangible Assets | 8.4B | 6.9B | 5.8B | 6.5B | 7.4B | 5.8B | |
| Inventory | 1.1B | 993M | 1.1B | 1.5B | 1.8B | 1.9B | |
| Common Stock | 10.2B | 10.3B | 10.4B | 10.4B | 12.0B | 6.1B | |
| Other Liab | 1.6B | 1.5B | 1.2B | 967M | 1.1B | 1.3B | |
| Other Assets | 1.8B | 2.8B | 2.3B | 2.3B | 2.6B | 2.7B | |
| Long Term Debt | 23.9B | 22.7B | 20.3B | 21.9B | 25.2B | 14.0B | |
| Good Will | 13.0B | 12.5B | 11.5B | 11.2B | 12.9B | 7.2B | |
| Net Tangible Assets | (22.3B) | (21.0B) | (19.5B) | (18.0B) | (16.2B) | (17.0B) | |
| Long Term Debt Total | 24.7B | 23.9B | 22.7B | 20.3B | 23.4B | 21.5B |
Bausch Health Key Income Statement Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Interest Expense | 1.5B | 1.4B | 1.5B | 1.3B | 1.5B | 1.6B | |
| Total Revenue | 8.0B | 8.4B | 8.1B | 8.8B | 10.1B | 10.6B | |
| Gross Profit | 5.8B | 6.0B | 5.8B | 6.2B | 7.1B | 7.5B | |
| Operating Income | 676M | 1.2B | 1.4B | 963M | 1.1B | 1.2B | |
| Ebit | 631.7M | 398.5M | 1.3B | 978.4M | 1.1B | 661.1M | |
| Ebitda | 2.6B | 1.9B | 2.6B | 2.2B | 2.6B | 1.5B | |
| Cost Of Revenue | 2.2B | 2.4B | 2.4B | 2.6B | 2.9B | 3.1B | |
| Income Before Tax | (934M) | (1.0B) | (129M) | (390M) | (351M) | (368.6M) | |
| Net Income | (559M) | (937M) | (212M) | (592M) | (532.8M) | (506.2M) | |
| Income Tax Expense | (375M) | (87M) | 83M | 221M | 198.9M | 208.8M | |
| Research Development | 452M | 465M | 529M | 604M | 694.6M | 729.3M | |
| Non Recurring | 106M | 136M | 234M | 15M | 13.5M | 12.8M | |
| Tax Provision | (375M) | (87M) | 83M | 221M | 254.2M | 266.9M | |
| Interest Income | 1.6B | 7M | 14M | 26M | 23.4M | 22.2M | |
| Net Interest Income | (1.5B) | (1.4B) | (1.5B) | (1.3B) | (1.5B) | (1.6B) |
Bausch Health Key Cash Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Change To Inventory | (77M) | (16M) | (198M) | (322M) | (289.8M) | (275.3M) | |
| Change In Cash | (1.4B) | 303M | (1.5B) | 371M | 333.9M | 350.6M | |
| Free Cash Flow | 802M | 1.1B | (996M) | 760M | 874M | 566.3M | |
| Depreciation | 1.8B | 1.6B | 1.4B | 1.3B | 1.5B | 926.7M | |
| Other Non Cash Items | 581M | 1.0B | (1.5B) | 778M | 894.7M | 939.4M | |
| Capital Expenditures | 309M | 283M | 268M | 272M | 312.8M | 170.4M | |
| Net Income | (559M) | (937M) | (212M) | (611M) | (549.9M) | (522.4M) | |
| End Period Cash Flow | 1.8B | 2.1B | 591M | 962M | 1.1B | 604.5M | |
| Change To Netincome | 1.4B | (376M) | (189M) | (2.5B) | (2.2B) | (2.1B) | |
| Investments | 4M | (4M) | 5M | (2.1B) | (1.9B) | (1.8B) | |
| Change Receivables | 39M | 170M | (229M) | (57M) | (65.6M) | (68.8M) | |
| Net Borrowings | 1.5B | (2.2B) | (1.4B) | (1.1B) | (972.9M) | (924.3M) |
Bausch Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Bausch Health's current stock value. Our valuation model uses many indicators to compare Bausch Health value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Bausch Health competition to find correlations between indicators driving Bausch Health's intrinsic value. More Info.Bausch Health Companies is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . At present, Bausch Health's Return On Equity is projected to increase slightly based on the last few years of reporting. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Bausch Health's earnings, one of the primary drivers of an investment's value.Bausch Health's Earnings Breakdown by Geography
Bausch Health Companies Systematic Risk
Bausch Health's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Bausch Health volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The function did not generate any output. Please change time horizon or modify your input parameters. The output start index for this execution was one with a total number of output elements of sixty. The Beta measures systematic risk based on how returns on Bausch Health Companies correlated with the market. If Beta is less than 0 Bausch Health generally moves in the opposite direction as compared to the market. If Bausch Health Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Bausch Health Companies is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Bausch Health is generally in the same direction as the market. If Beta > 1 Bausch Health moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in Bausch Health Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Bausch Health's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Bausch Health growth as a starting point in their analysis.
Price Earnings To Growth Ratio |
|
Bausch Health January 18, 2025 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Bausch Health help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Bausch Health Companies. We use our internally-developed statistical techniques to arrive at the intrinsic value of Bausch Health Companies based on widely used predictive technical indicators. In general, we focus on analyzing Bausch Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Bausch Health's daily price indicators and compare them against related drivers.
| Information Ratio | (0.05) | |||
| Maximum Drawdown | 21.5 | |||
| Value At Risk | (5.32) | |||
| Potential Upside | 4.27 |
Complementary Tools for Bausch Stock analysis
When running Bausch Health's price analysis, check to measure Bausch Health's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bausch Health is operating at the current time. Most of Bausch Health's value examination focuses on studying past and present price action to predict the probability of Bausch Health's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bausch Health's price. Additionally, you may evaluate how the addition of Bausch Health to your portfolios can decrease your overall portfolio volatility.
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Stocks Directory Find actively traded stocks across global markets | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios |